AU2016396401B2 - In vitro method for identifying thoracic aortic aneurysms (TAA) in a subject - Google Patents

In vitro method for identifying thoracic aortic aneurysms (TAA) in a subject Download PDF

Info

Publication number
AU2016396401B2
AU2016396401B2 AU2016396401A AU2016396401A AU2016396401B2 AU 2016396401 B2 AU2016396401 B2 AU 2016396401B2 AU 2016396401 A AU2016396401 A AU 2016396401A AU 2016396401 A AU2016396401 A AU 2016396401A AU 2016396401 B2 AU2016396401 B2 AU 2016396401B2
Authority
AU
Australia
Prior art keywords
mice
taa
amino
aortic
adamtsl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2016396401A
Other languages
English (en)
Other versions
AU2016396401A1 (en
Inventor
Miguel Ramón CAMPANERO GARCIA
Nerea MÉNDEZ-BARBERO
Jorge OLLER PEDROSA
Juan Miguel Redondo Moya
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Centro Nacional De Investigaciones Cardiovasculares Carlos Iii (fsp)
Consejo Superior de Investigaciones Cientificas CSIC
Universidad Autonoma de Madrid
Original Assignee
Centro Nac De Investigaciones Cardiovasculares Carlos Iii F S P
Consejo Superior de Investigaciones Cientificas CSIC
Universidad Autonoma de Madrid
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Centro Nac De Investigaciones Cardiovasculares Carlos Iii F S P, Consejo Superior de Investigaciones Cientificas CSIC, Universidad Autonoma de Madrid filed Critical Centro Nac De Investigaciones Cardiovasculares Carlos Iii F S P
Publication of AU2016396401A1 publication Critical patent/AU2016396401A1/en
Application granted granted Critical
Publication of AU2016396401B2 publication Critical patent/AU2016396401B2/en
Ceased legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/0004—Oxidoreductases (1.)
    • C12N9/0071—Oxidoreductases (1.) acting on paired donors with incorporation of molecular oxygen (1.14)
    • C12N9/0073—Oxidoreductases (1.) acting on paired donors with incorporation of molecular oxygen (1.14) with NADH or NADPH as one donor, and incorporation of one atom of oxygen 1.14.13
    • C12N9/0075—Nitric-oxide synthase (1.14.13.39)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y114/00—Oxidoreductases acting on paired donors, with incorporation or reduction of molecular oxygen (1.14)
    • C12Y114/13—Oxidoreductases acting on paired donors, with incorporation or reduction of molecular oxygen (1.14) with NADH or NADPH as one donor, and incorporation of one atom of oxygen (1.14.13)
    • C12Y114/13039—Nitric-oxide synthase (NADPH dependent) (1.14.13.39)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/914—Hydrolases (3)
    • G01N2333/948—Hydrolases (3) acting on peptide bonds (3.4)
    • G01N2333/95—Proteinases, i.e. endopeptidases (3.4.21-3.4.99)
    • G01N2333/964—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue
    • G01N2333/96402—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from non-mammals
    • G01N2333/96405—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from non-mammals in general
    • G01N2333/96408—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from non-mammals in general with EC number
    • G01N2333/96419—Metalloendopeptidases (3.4.24)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/32—Cardiovascular disorders
    • G01N2800/329—Diseases of the aorta or its branches, e.g. aneurysms, aortic dissection

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Urology & Nephrology (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Pathology (AREA)
  • Food Science & Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
AU2016396401A 2016-03-07 2016-12-30 In vitro method for identifying thoracic aortic aneurysms (TAA) in a subject Ceased AU2016396401B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP16382103.6 2016-03-07
EP16382103 2016-03-07
PCT/EP2016/082925 WO2017153023A1 (en) 2016-03-07 2016-12-30 In vitro method for identifying thoracic aortic aneurysms (taa) in a subject

Publications (2)

Publication Number Publication Date
AU2016396401A1 AU2016396401A1 (en) 2018-10-25
AU2016396401B2 true AU2016396401B2 (en) 2023-07-13

Family

ID=55524277

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2016396401A Ceased AU2016396401B2 (en) 2016-03-07 2016-12-30 In vitro method for identifying thoracic aortic aneurysms (TAA) in a subject

Country Status (8)

Country Link
US (2) US10907135B2 (enExample)
EP (1) EP3427061B1 (enExample)
JP (1) JP7057976B2 (enExample)
AU (1) AU2016396401B2 (enExample)
BR (1) BR112018068045A2 (enExample)
CA (1) CA3017042C (enExample)
ES (1) ES2965961T3 (enExample)
WO (1) WO2017153023A1 (enExample)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2555790B1 (es) 2014-06-05 2016-10-13 Consejo Superior De Investigaciones Científicas (Csic) Método de obtención de un array de micropartículas planares con multiplexado molecular superficial, array obtenido y su uso
US11143659B2 (en) 2015-01-27 2021-10-12 Arterez, Inc. Biomarkers of vascular disease
US11459612B2 (en) 2015-12-01 2022-10-04 Centro Nacional De Investigaciones Cardiovasculares Carlos Iii (F.S.P.) Method for diagnosing cardiomyopathies
BR112020010316A2 (pt) 2017-11-24 2020-10-20 Consejo Superior De Investigaciones Científicas (Csic) cepa de vacina de brucella modificada para o tratamento de brucelose
JP2021513993A (ja) * 2018-02-19 2021-06-03 ザ ジェネラル ホスピタル コーポレイション 血管疾患を処置するための方法および組成物
EP3830293B1 (en) * 2018-07-27 2025-01-15 The Regents of the University of California Tetrahydrobiopterin as biomarker for thoracic aortic aneurysm
WO2021140019A1 (en) * 2020-01-10 2021-07-15 Deutsches Herzzentrum München Des Freistaates Bayern Klinik An Der Technischen Universität München Diagnosis of an aortic dissection by detecting a specific biomarker in a blood sample
US20210318336A1 (en) * 2020-04-09 2021-10-14 The Trustees Of The University Of Pennsylvania Methods for treating aortic aneurysm disease
WO2022219196A1 (en) * 2021-04-16 2022-10-20 Centro Nacional De Investigaciones Cardiovasculares Carlos Iii (F.S.P.) Method for the diagnosis, prognosis and/or treatment of thoracic aortic aneurysm

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030109522A1 (en) * 2001-09-24 2003-06-12 Manning Pamela T. Ophthalmologic treatment methods using selective iNOS inhibitors
US20150203916A1 (en) * 2012-06-27 2015-07-23 Music Foundation For Research Development Plasma analytes predict diagnosis and prognosis of thoracic aortic aneurysm
ES2555790B1 (es) 2014-06-05 2016-10-13 Consejo Superior De Investigaciones Científicas (Csic) Método de obtención de un array de micropartículas planares con multiplexado molecular superficial, array obtenido y su uso
ES2612340B1 (es) 2015-10-27 2018-03-09 Consejo Superior De Investigaciones Científicas (Csic) Sensor, aparato y procedimiento para la determinación de la concentración de solutos en disoluciones
US11459612B2 (en) 2015-12-01 2022-10-04 Centro Nacional De Investigaciones Cardiovasculares Carlos Iii (F.S.P.) Method for diagnosing cardiomyopathies
RU2018141858A (ru) 2016-04-29 2020-05-29 Универсидад Аутонома Де Мадрид Составы с липидными системами, несущими биоактивные соединения для применения в качестве иммунотерапевтического потенцирующего средства или адъюванта для пациентов с раком или иммунологическими нарушениями
US10683493B2 (en) 2016-05-18 2020-06-16 Consejo Superior De Investigaciones Científicas Fusion proteins comprising an aldolase enzyme joined to a maltose binding protein
EP3681515A1 (en) 2017-09-15 2020-07-22 Fundación para la Investigación Biomédica del Hospital Universitario de la Paz (FIBHULP) Mafg as a potential therapeutic target to restore chemosensitivity in platinum-resistant cancer cells
US20200345701A1 (en) 2017-11-02 2020-11-05 Consejo Superior De Investigaciones Cientificas (Csic) Use of statins in overcoming resistance to beta-lactam antibiotics in bacterial species synthetizing isoprenoids using the mevalonate synthetic pathway
BR112020010316A2 (pt) 2017-11-24 2020-10-20 Consejo Superior De Investigaciones Científicas (Csic) cepa de vacina de brucella modificada para o tratamento de brucelose
WO2019234189A1 (en) 2018-06-06 2019-12-12 Centro Nacional De Investigaciones Cardiovasculares Carlos Iii (F.S.P.) Enhanced trained immunity in myeloid cells by ship-1 inhibition
JP7260341B2 (ja) 2019-03-06 2023-04-18 スタンレー電気株式会社 車両用灯具の制御装置、車両用灯具の制御方法、車両用灯具システム

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Tan CK, et al. SMAD3 deficiency promotes inflammatory aortic aneurysms in angiotensin II–infused mice via activation of iNOS. Journal of the American Heart Association. 2013 Jun 19;2(3):e000269. *

Also Published As

Publication number Publication date
US20210363501A1 (en) 2021-11-25
US20190112582A1 (en) 2019-04-18
BR112018068045A2 (pt) 2019-01-08
ES2965961T3 (es) 2024-04-17
CA3017042A1 (en) 2017-09-14
EP3427061A1 (en) 2019-01-16
US12163161B2 (en) 2024-12-10
US10907135B2 (en) 2021-02-02
JP2019510081A (ja) 2019-04-11
WO2017153023A1 (en) 2017-09-14
EP3427061B1 (en) 2023-12-06
CA3017042C (en) 2024-02-20
AU2016396401A1 (en) 2018-10-25
EP3427061C0 (en) 2023-12-06
JP7057976B2 (ja) 2022-04-21

Similar Documents

Publication Publication Date Title
US12163161B2 (en) In vitro method for identifying thoracic aortic aneurysms (TAA) in a subject
US11331290B2 (en) Niclosamide for the treatment of cancer metastasis
JP6854766B2 (ja) チロシンキナーゼ阻害剤を用いる組成物および方法
US9730922B2 (en) Combined therapy for cystic fibrosis
US20110171193A1 (en) Compositions and methods for treating pulmonary hypertension
EP2217223A2 (en) Methods and compositions for measuring wnt activation and for treating wnt-related cancers
JP6822412B2 (ja) 妊娠高血圧腎症のための診断アッセイ及び治療
JP2021513993A (ja) 血管疾患を処置するための方法および組成物
Wang et al. Angiotensin II receptor blocker LCZ696 attenuates cardiac remodeling through the inhibition of the ERK signaling pathway in mice with pregnancy-associated cardiomyopathy
US20080293936A1 (en) Novel inhibitors of lysyl oxidase
US20220193053A1 (en) Cystic fibrosis transmembrane conductance regulator modulators for treating autosomal dominant polycystic kidney disease
Redondo et al. In vitro method for identifying thoracic aortic aneurysms (taa) in a subject
Hu et al. Myocardial ischemia/reperfusion-induced glycolysis enhances damage through TRPM7 histone lactylation
US9457016B2 (en) Methods for treating polycystic kidney disease
US20220372491A1 (en) Treatment of renal cystic disease
JP7525591B2 (ja) 心機能不全を予測及び処置するための方法
Sabio et al. P38 inhibitors for the treatment and prophylaxis of liver cancer
Charlestown sGCα1β1 attenuates cardiac dysfunction and mortality in murine inflammatory shock 1 models. 2

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)
MK14 Patent ceased section 143(a) (annual fees not paid) or expired